AVR — Anteris Technologies Global Corp.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 2011514 ·
Last close
$7.84
Market Cap
$763.16M
52W High
$11.06
52W Low
$5.94
ADV30
1,344,670
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | — | — | — | — | — | — | — |
| Mar 2025 | — | — | — | — | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,100,678
Investing CF
$-553,064
Financing CF
$18,486,944
CapEx
$-553,064
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.09
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-257,012,631
Inventory
$459,603
Receivables
$2,095,604
ST Investments
—
EBIT TTM
$-21,782,712
Pretax Income TTM
$-21,794,452
Interest Exp TTM
$11,740
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,851,000
EBITDA
$-94,434,000
Free Cash Flow
$-52,655,876
Enterprise Value
$484,164,864
Total Cash
$282,699,008
Total Debt
$3,735,000
Shares Out
97,342,203
Trailing EPS
$-2.22
Book Value
$2.86
ROE
-59.2%
ROA
-34.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | — | — | — |
| Dec 2024 | — | — | — | — | — | — | — |
| Dec 2023 | 2,734,821 | -46,656,491 | -46,021,841 | 30,527,440 | 11,629,367 | — | -34,631,516 |
| Dec 2022 | 3,200,711 | -31,487,645 | -30,563,800 | 15,985,506 | 6,952,284 | — | -29,416,702 |
| Dec 2021 | 5,830,534 | -16,320,961 | -17,171,057 | 21,433,693 | 10,908,758 | — | -14,438,162 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.98
Max Pain — expiry 2026-08-21
max pain strike: $7.50 · spot: $7.84 · call oi: 1,822 · put oi: 2,069
Expected Move to 2026-08-21:
±$1.32
(16.90%) —
implied range
$6.52 –
$9.17
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SGP | SpyGlass Pharma, Inc. | $753.25M | $22.53 | — |
| SIBN | SI-BONE, Inc. | $787.64M | $17.76 | — |
| SSII | SS Innovations International, Inc. | $796.52M | $3.98 | — |
| CBLL | Ceribell, Inc. | $671.21M | $17.69 | — |
| INMD | InMode Ltd. | $870.26M | $15.14 | — |
News headlines (Yahoo Finance, 1h cache)
TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge
2026-06-15 12:05 · Yahoo
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
2026-06-08 23:22 · Yahoo
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
2026-06-08 10:00 · Yahoo
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation
2026-05-13 20:00 · Yahoo
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
2026-05-13 12:39 · Yahoo
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
2026-05-13 01:33 · Yahoo
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
2026-05-12 23:43 · Yahoo
Anteris Announces Results for the First Quarter of 2026
2026-05-12 23:00 · Yahoo
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances
2026-05-07 01:45 · Yahoo
Anteris treats first US patients in DurAVR pivotal trial
2026-05-07 01:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.